

Kieran F Docherty

List of Publications by Citations

Source: <https://exaly.com/author-pdf/5003738/kieran-f-docherty-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

47
papers

3,152
citations

18
h-index

56
g-index

61
ext. papers

5,240
ext. citations

11
avg, IF

5.02
L-index

#	Paper	IF	Citations
47	Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. <i>New England Journal of Medicine</i> , 2019 , 381, 1995-2008	59.2	2021
46	Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2020 , 323, 1353-1368	27.4	155
45	Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial. <i>Circulation</i> , 2020 , 141, 90-99	16.7	130
44	Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF). <i>Circulation</i> , 2021 , 143, 516-525	16.7	85
43	Effects of dapagliflozin in DAPA-HF according to background heart failure therapy. <i>European Heart Journal</i> , 2020 , 41, 2379-2392	9.5	80
42	Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF. <i>Circulation</i> , 2021 , 143, 298-309	16.7	69
41	Lung Ultrasound in Acute Heart Failure: Prevalence of Pulmonary Congestion and Short- and Long-Term Outcomes. <i>JACC: Heart Failure</i> , 2019 , 7, 849-858	7.9	65
40	Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF. <i>Circulation</i> , 2020 , 142, 1040-1054	16.7	52
39	Statin treatment of children with familial hypercholesterolemia--trying to balance incomplete evidence of long-term safety and clinical accountability: are we approaching a consensus?. <i>Atherosclerosis</i> , 2013 , 226, 315-20	3.1	48
38	Cost-effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health-economic analysis of DAPA-HF. <i>European Journal of Heart Failure</i> , 2020 , 22, 2147-2156	12.3	41
37	Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF). <i>European Heart Journal</i> , 2020 , 41, 3402-3418	9.5	40
36	How robust are clinical trials in heart failure?. <i>European Heart Journal</i> , 2017 , 38, 338-345	9.5	37
35	Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction. <i>JAMA Cardiology</i> , 2021 , 6, 499-507	16.2	35
34	Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF. <i>Diabetes Care</i> , 2021 , 44, 586-594	14.6	24
33	Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists: An Analysis of DAPA-HF. <i>JACC: Heart Failure</i> , 2021 , 9, 254-264	7.9	23
32	Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF. <i>European Heart Journal</i> , 2021 , 42, 3727-3738	9.5	22
31	Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction: A Prespecified Analysis of DAPA-HF. <i>Circulation</i> , 2020 , 142, 1623-1632	16.7	20

30	Renin-angiotensin system blockers, risk of SARS-CoV-2 infection and outcomes from COVID-19: systematic review and meta-analysis. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020 ,	6.4	20
29	The Dapagliflozin and Prevention of Adverse outcomes in Heart Failure trial (DAPA-HF) in context. <i>European Heart Journal</i> , 2021 , 42, 1199-1202	9.5	18
28	Effect of dapagliflozin on anaemia in DAPA-HF. <i>European Journal of Heart Failure</i> , 2021 , 23, 617-628	12.3	14
27	Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trial. <i>European Journal of Heart Failure</i> , 2021 , 23, 601-613	12.3	14
26	Effect of Nephilysin Inhibition on Left Ventricular Remodeling in Patients With Asymptomatic Left Ventricular Systolic Dysfunction Late After Myocardial Infarction. <i>Circulation</i> , 2021 , 144, 199-209	16.7	14
25	Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF. <i>Circulation</i> , 2021 , 143, 1962-1972	16.7	13
24	Sacubitril/Valsartan in Asian Patients with Heart Failure with Reduced Ejection Fraction. <i>Korean Circulation Journal</i> , 2019 , 49, 469-484	2.2	12
23	Sex differences in procedural and clinical outcomes following rotational atherectomy. <i>Catheterization and Cardiovascular Interventions</i> , 2020 , 95, 232-241	2.7	12
22	Effect of Dapagliflozin in DAPA-HF According to Background Glucose-Lowering Therapy. <i>Diabetes Care</i> , 2020 , 43, 2878-2881	14.6	8
21	Effects of dapagliflozin in heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: an analysis of DAPA-HF. <i>European Journal of Heart Failure</i> , 2021 , 23, 632-643	12.3	8
20	Efficacy and Safety of Dapagliflozin in Men and Women With Heart Failure With Reduced Ejection Fraction: A Prespecified Analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure Trial. <i>JAMA Cardiology</i> , 2021 , 6, 678-689	16.2	7
19	Effect of sacubitril/valsartan on investigator-reported ventricular arrhythmias in PARADIGM-HF.. <i>European Journal of Heart Failure</i> , 2021 ,	12.3	6
18	SOLOIST-WHF and updated meta-analysis: sodium-glucose co-transporter 2 inhibitors should be initiated in patients hospitalized with worsening heart failure. <i>European Journal of Heart Failure</i> , 2021 , 23, 27-30	12.3	6
17	Rationale and methods of a randomized trial evaluating the effect of neprilysin inhibition on left ventricular remodelling. <i>ESC Heart Failure</i> , 2021 , 8, 129-138	3.7	6
16	Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index. <i>European Journal of Heart Failure</i> , 2021 , 23, 1662-1672	12.3	6
15	Angiotensin receptor-neprilysin inhibitors: A new paradigm in heart failure with reduced ejection fraction. <i>International Journal of Cardiology</i> , 2019 , 281, 179-185	3.2	5
14	Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HF. <i>European Journal of Heart Failure</i> , 2021 ,	12.3	5
13	Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials. <i>Lancet Diabetes and Endocrinology</i> , 2021 ,	18.1	3

12	PIONEER-HF: a new frontier in the role of neprilysin inhibition in the management of heart failure with reduced ejection fraction. <i>Cardiovascular Research</i> , 2019 , 115, e136-e139	9.9	2
11	Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial. <i>Circulation: Heart Failure</i> , 2021 , CIRCHEARTFAILURE121008837	7.6	2
10	Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis of a Phase 3 Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2021 , 6, 1298-1305	16.2	2
9	Sex differences in congestive markers in patients hospitalized for acute heart failure. <i>ESC Heart Failure</i> , 2021 , 8, 1784-1795	3.7	2
8	Serial Assessment of High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients with Heart Failure with Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial. <i>Circulation</i> , 2021 ,	16.7	1
7	Efficacy of Dapagliflozin in Black Versus White Patients With Heart Failure and Reduced Ejection Fraction.. <i>JACC: Heart Failure</i> , 2022 , 10, 52-64	7.9	1
6	Relationship of Dapagliflozin With Serum Sodium: Findings From the DAPA-HF Trial.. <i>JACC: Heart Failure</i> , 2022 , 10, 306-318	7.9	1
5	Effect of Dapagliflozin, Compared With Placebo, According to Baseline Risk in DAPA-HF.. <i>JACC: Heart Failure</i> , 2022 , 10, 104-118	7.9	0
4	Developments in Exercise Capacity Assessment in Heart Failure Clinical Trials and the Rationale for the Design of METEORIC-HF.. <i>Circulation: Heart Failure</i> , 2022 , CIRCHEARTFAILURE121008970	7.6	0
3	Effect of single and dual renin-angiotensin blockade on stroke in patients with and without diabetes in VALIANT. <i>European Stroke Journal</i> , 2016 , 1, 93-100	5.6	
2	Genomics and Pharmacogenomics of Lipid-Lowering Therapies 2014 , 715-746		
1	Chest pain with less than 20% change in high sensitivity troponin T - a low risk cohort?. <i>Acta Cardiologica</i> , 2020 , 75, 149-155	0.9	